For example, Liu and coworkers demonstrated that the delivery of vitamin D-based drug payloads via tumor-targeted epidermal growth factor receptor (EGFR) liposomal nanoparticles has promise as a new therapy of EGFR tyrosine kinase inhibitors for resisting lung cancer [24]. This evidence concerns the gene EGFR and neoplasm.